Abstracts tagged "canakinumab and juvenile idiopathic arthritis (JIA)"

Abstract Number: 3 • 2017 Pediatric Rheumatology Symposium
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Rayfel Schneider⁴, Isabelle Koné-Paut⁵, Kenneth N. Schikler⁶, Katherine Marzan⁴, Nico Wulffraat², Shai Padeh⁷, Vyacheslav Chasnyk⁷, Carine Wouters⁷, Jasmin B. Kuemmerle-Deschner⁷, Tilmann Kallinich⁷, Bernard Lauwerys⁸, Elie Haddad⁴, Evgeny L Nasonov⁷, Maria Trachana⁷, Olga Vougiouka⁷, Karolynn Leon⁹, Antonio Speziale¹⁰, Karine Lheritier¹⁰, Eleni Vritzali¹¹, Alberto Martini⁷ and Daniel Lovell⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴PRCSG, Cincinnati, OH, ⁵Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁶PRCSG, Cincinatti, OH, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic arthritis…
Abstract Number: 44 • 2017 Pediatric Rheumatology Symposium
Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Isabelle Koné-Paut⁴, Katherine Marzan⁵, Nico Wulffraat², Rayfel Schneider⁵, Shai Padeh⁶, Vyacheslav Chasnyk⁶, Carine Wouters⁶, Jasmin B. Kuemmerle-Deschner⁶, Tilmann Kallinich⁶, Bernard Lauwerys⁷, Elie Haddad⁵, Evgeny L Nasonov⁶, Maria Trachana⁶, Olga Vougiouka⁶, Karolynn Leon⁸, Eleni Vritzali⁹, Karine Lheritier¹⁰, Alberto Martini⁶ and Daniel Lovell⁵, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁵PRCSG, Cincinnati, OH, ⁶PRINTO-Istituto Gaslini, Genova, Italy, ⁷Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The management of SJIA with biological therapies is aimed to achieve and maintain clinical remission (CR), and accordingly taper corticosteroids (CS). Canakinumab (CAN) demonstrated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].